With the accumulated evidence in recent years, we performed a systematic review and meta-analysis to explore the prognostic significance of PD-L1 blood markers, including sPD-L1, CTC PD-L1 and exoPD-L1, in NSCLC patients treated with ICIs. Here, SPDL1 is linked to non-small cell lung carcinoma.